Boston Scientific (BSX) - FREE Research Report

Mario Ernest who is Director at Boston Scientific sold 17,104 shares at $12.80 on Feb. 7, 2014. Following this transaction, the Director owned 347,855 shares meaning that the stake was reduced by 4.69% with the 17,104-share transaction.

The shares most recently traded at $13.01, up $0.21, or 1.61% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 230,466
  • 24-Week # shares sold: 430,902

The average volume for Boston Scientific has been 11.5 million shares per day over the past 30 days. Boston Scientific has a market cap of $17.1 billion and is part of the health care sector and health services industry. Shares are up 8.98% year-to-date as of the close of trading on Friday.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Currently there are 8 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Jim Cramer: The S&P 500 Isn’t as Passive as You Might Think

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

3 Stocks Reiterated As A Buy: CFN, UTX, WHR

Insider Trading Alert - CFN, VSR And CAVM Traded By Insiders

Jim Cramer on the Stock Market: Spinoffs Are in Vogue